New results from a vaccine trial are indicating that the Pfizer BioNTech COVID-19 vaccine is safe and effective if administered to children between the ages of 5 and 11. The companies issued the statement on Monday, planning to also submit the data for regulatory approval to the European Medicines Agency and the American Federal Drug Agency.
The companies stated that the vaccine was safe, well tolerated and showed robust neutralizing antibody responses for the under-12 age group. Results in children under 5 years of age are also being expected as soon as later this year. With a favorable safety profile and robust neutralizing antibody response in kids aged 5-11 shown in trial results, a two dose regimen is being administered with 21 days set apart. Kids were administered a smaller dose than those used for above 12 years of age.
Chairman and CEO of Pfizer Albert Bourla stated that over the past nine months, hundreds of millions of people aged 12 and older from across the global have received their jab. The companies are now eager to extend the protection to the younger populations so as to quicken the return to normalcy.
#MaltaDaily